SMER-28

Research use only, not for human use.

A small-molecule enhancer/inducer of Autophagy; decreases the levels of Aβ peptide (EC50=10 uM) and APP-CTF (EC50 of 20 uM) in a γ-secretase-independent manner in primary neuronal cultures, Atg5, Beclin1 and Ulk1 are shown to be involved in the degradation of Aβ and APP-CTF.

A small-molecule enhancer/inducer of Autophagy; decreases the levels of Aβ peptide (EC50=10 uM) and APP-CTF (EC50 of 20 uM) in a γ-secretase-independent manner in primary neuronal cultures, Atg5, Beclin1 and Ulk1 are shown to be involved in the degradation of Aβ and APP-CTF; enhances erythropoiesis in a range of in vitro and in vivo models of DBA, and protects against neurodegeneration in Drosophila model of Huntington’s disease.

SMER28 (5-200 μM; 24 hours) shows a dose dependent decline of cell viability. Cell Viability Assay Cell Line:MMS1 cells Concentration:5, 25, 50, 75, 100, 150, 200 μM Incubation Time:24 hours Result:Showed a dose dependent decline of cell viability.

SMER28 (15-65 mg/kg; i.h.; daily, two days before irradiation and during the three days of irradiation) significantly protects against post-irradiation weight loss and enhances survival of mice at 65 mg/kg. Animal Model:14 to 16 weeks male mice (Balb/c)Dosage:15, 65 mg/kg Administration:Subcutaneous injection; two days before irradiation and during the three days of irradiation (total 5 days)Result:Significantly protected against post-irradiation weight loss and enhanced survival of mice at 65 mg/kg.

SMER28

Autophagy

Autophagy

Autophagy

Neurological Disease

——

307538-42-7

264.1212

C11H10BrN3

>98% (HPLC)

DMSO: ≥ 32 mg/mL

C=CCNC1=C2C=C(Br)C=CC2=NC=N1

4-Quinazolinamine, 6-bromo-N-2-propen-1-yl-

(-20℃)

With Ice Pack

≥ 2 years